Pelthos Therapeutics Inc. has officially announced a merger with Castle Creek Biosciences, marking a significant step in its growth strategy within the biological products industry. The merger is expected to enhance Pelthos's capabilities and market position, as it aims to integrate Castle Creek's innovative assets into its operations.

On October 30, 2026, Pelthos, along with its wholly owned subsidiaries, entered into an Agreement and Plan of Merger with Castle Creek and Paragon Biosciences, LLC, which acts as the securityholder representative. This merger is structured to qualify as a reorganization under federal tax law, a move that could provide various financial benefits to the companies involved.

Pelthos Therapeutics, listed under the ticker PTHS on the NYSE, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company has undergone several name changes in the past, previously known as Channel Therapeutics Corp and Chromocell Therapeutics Corp.

The merger agreement outlines that Castle Creek will merge with Pelthos's subsidiary, with Castle Creek continuing as a wholly owned subsidiary of Pelthos. Following this, Castle Creek will subsequently merge into another subsidiary of Pelthos. This two-step merger process is designed to streamline operations and enhance the overall value proposition of Pelthos.

In terms of consideration for Castle Creek stockholders, the agreement stipulates that they will receive a total of 5,200,000 shares of Pelthos common stock, along with potential milestone payments based on clinical achievements and sales performance of Castle Creek's product, D-Fi. These milestone payments could total up to $300 million, contingent on specific performance metrics being met.

The merger also includes a PIPE (Private Investment in Public Equity) financing component, wherein Pelthos has entered into a securities purchase agreement with several investors, including Ligand Pharmaceuticals and Nomis Bay Ltd. The PIPE financing is expected to raise approximately $57.5 million, which will be used for working capital and to repay certain debts of Castle Creek.

Following the merger, Pelthos anticipates that Castle Creek stockholders will own approximately 32.5% of the company, while existing Pelthos securityholders will hold about 67.5% of the common stock, excluding contingent shares. This ownership structure is designed to align the interests of both parties as they move forward together.

The merger agreement also includes provisions for the treatment of equity awards from Castle Creek, ensuring that outstanding options and warrants are handled appropriately during the transition. Additionally, both companies have agreed to customary representations and warranties, which will help protect their interests throughout the merger process.

As part of the merger, Pelthos's board of directors will expand from eight to ten members, incorporating two new directors designated by Castle Creek. This change is expected to bring additional expertise and perspectives to the board as Pelthos navigates its new direction.

The consummation of the merger is subject to various closing conditions, including stockholder approvals and regulatory clearances. If successful, this merger could position Pelthos as a more formidable player in the biological products market, potentially leading to enhanced product offerings and increased market share.

Looking ahead, Pelthos will need to navigate the complexities of integrating Castle Creek's operations while ensuring compliance with all regulatory requirements. The company has indicated that it will file a registration statement with the SEC to facilitate the issuance of shares related to the merger and PIPE financing.

In conclusion, Pelthos Therapeutics's merger with Castle Creek Biosciences represents a strategic move aimed at strengthening its position within the biological products industry. With significant financial backing and a clear plan for integration, Pelthos is poised to leverage this merger to drive future growth and innovation.